Home > Publications database > Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. > print

001     119375
005     20240228145436.0
024 7 _ |a 10.1038/leu.2017.22
|2 doi
024 7 _ |a pmid:28096533
|2 pmid
024 7 _ |a 0887-6924
|2 ISSN
024 7 _ |a 1476-5551
|2 ISSN
024 7 _ |a altmetric:16144815
|2 altmetric
037 _ _ |a DKFZ-2017-00129
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Schlenk, Richard
|0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
|b 0
|e First author
|u dkfz
245 _ _ |a Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.
260 _ _ |a Basingstoke
|c 2017
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1511514422_23139
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Frech, P.
|b 1
700 1 _ |a Weber, D.
|b 2
700 1 _ |a Brossart, P.
|b 3
700 1 _ |a Horst, H-A
|b 4
700 1 _ |a Kraemer, D.
|b 5
700 1 _ |a Held, G.
|b 6
700 1 _ |a Ringhoffer, M.
|b 7
700 1 _ |a Burchardt, A.
|b 8
700 1 _ |a Kobbe, G.
|b 9
700 1 _ |a Götze, K.
|b 10
700 1 _ |a Nachbaur, D.
|b 11
700 1 _ |a Fischer, T.
|b 12
700 1 _ |a Lübbert, M.
|b 13
700 1 _ |a Salih, H. R.
|b 14
700 1 _ |a Salwender, H.
|b 15
700 1 _ |a Wulf, G.
|b 16
700 1 _ |a Koller, E.
|b 17
700 1 _ |a Wattad, M.
|b 18
700 1 _ |a Fiedler, W.
|b 19
700 1 _ |a Kremers, S.
|b 20
700 1 _ |a Kirchen, H.
|b 21
700 1 _ |a Hertenstein, B.
|b 22
700 1 _ |a Paschka, P.
|b 23
700 1 _ |a Gaidzik, V. I.
|b 24
700 1 _ |a Teleanu, V.
|b 25
700 1 _ |a Heuser, M.
|b 26
700 1 _ |a Thol, F.
|b 27
700 1 _ |a Döhner, K.
|b 28
700 1 _ |a Krauter, J.
|b 29
700 1 _ |a Ganser, A.
|b 30
700 1 _ |a Döhner, H.
|b 31
700 1 _ |a and
|b 32
|e Collaboration Author
700 1 _ |a German-Austrian AMLSG
|b 33
|e Collaboration author
773 _ _ |a 10.1038/leu.2017.22
|0 PERI:(DE-600)2008023-2
|n 5
|p 1217-1220
|t Leukemia
|v 31
|y 2017
|x 1476-5551
909 C O |o oai:inrepo02.dkfz.de:119375
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LEUKEMIA : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b LEUKEMIA : 2015
920 1 _ |0 I:(DE-He78)G040-20160331
|k G040
|l Klinische Studienzentrale
|x 0
920 1 _ |0 I:(DE-He78)G100-20160331
|k G100
|l Translationale Onkologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G040-20160331
980 _ _ |a I:(DE-He78)G100-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21